Ocugen posts corporate presentation with clinical data; 6-month treated/untreated rates shown

Ocugen, Inc.

Presentation shows 52% vs 44% for treated and untreated eyes at 6-month timeline.
Data likely from OCU400 gene therapy program for retinitis pigmentosa.
Presentation posted on company website March 3, 2025; used for investor discussions.
No formal guidance or regulatory update provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.